ESMO Asia 2019 | MIMS Malaysia

ARCHER 1050: Persistent OS benefit with dacomitinib vs gefitinib in EGFR+ advanced NSCLC

Roshini Claire Anthony, 20191219140101

First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.

PROfound: A double hit for olaparib in mCRPC harbouring certain mutations

Elvira Manzano, 20191209023331

Treatment with the (ADP-ribose) polymerase (PARP) inhibitor olaparib led to a statistically significant and clinically meaningful improvement in radiological progression-free survival (rPFS) vs physician’s choice of new hormonal agent (NHA) enzalutamide or abiraterone + prednisone in men with advanced prostate cancer harbouring certain gene mutations that were identified through genetic testing, the PROfound* trial has shown.

MYSTIC: Durvalumab ± tremelimumab vs chemotherapy may benefit Asian patients with metastatic NSCLC

Elaine Soliven, 20191209000000

Treatment with durvalumab with or without tremelimumab appeared to improve overall survival (OS) in Asian patients with metastatic non-small cell lung cancer (mNSCLC) compared with chemotherapy (CT) in the first-line setting, according to a post hoc analysis of the MYSTIC* trial presented at ESMO Asia 2019.

Circulating miR-155 shows promise as therapeutic monitoring marker in breast cancer

Stephen Padilla, 20191205120000

Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).

Slideshow: Highlights from the ESMO Asia 2019.

20191205052501

Slideshow: Highlights from the ESMO Asia 2019.

CASPIAN: Durvalumab + platinum-etoposide improves OS in ES-SCLC

Elaine Soliven, 20191205000000

First-line treatment with durvalumab + platinum-etoposide (EP)* improves overall survival (OS) in Asian patients with extensive-stage small-cell lung cancer (ES-SCLC), according to the CASPIAN** study.

Ultrasound-guided core biopsy foretells treatment outcome in breast cancer

Jairia Dela Cruz, 20191204150000

In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.

Immunotherapy not superior to chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma

Stephen Padilla, 20191204120000

There appears to be no significant survival difference between first-line immune checkpoint inhibitor (ICI) and carboplatin-based chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma patients, according to a Taiwan study presented at the recent 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).

C-reactive protein/albumin ratio a useful prognostic marker in pancreatic cancer

Jairia Dela Cruz, 20191204060000

C-reactive protein/albumin ratio (CAR) can provide prognostic information on survival in pancreatic cancer, such that patients with high pretreatment CAR may have poorer overall survival, according to a study presented at the ESMO Asia 2019 Congress.

Trastuzumab biosimilar HLX02 shows equivalency in HER2+ breast cancer

Pearl Toh, 20191203180010

The trastuzumab biosimilar HLX02 was equivalent to the reference trastuzumab in terms of overall response rate (ORR) in women with HER2*-positive (HER2+) breast cancer, along with similar safety profile, reveals a study presented at ESMO Asia 2019.